Agilent Receives a New Rating from Top Analyst

By Carrie Williams

Jefferies analyst John Difucci reiterated a Buy rating on Agilent (NYSE: A) yesterday and set a price target of $59. The company’s shares closed yesterday at $53.31, close to its 52-week high of $54.82.

According to TipRanks.com, Difucci is a top 100 analyst with an average return of 14.1% and a 67.7% success rate. Difucci covers the Technology sector, focusing on stocks such as SS&C Technologies Holdings, Palo Alto Networks, and CommVault Systems.

Currently, the analyst consensus on Agilent is Strong Buy and the average price target is $55.67, representing a 4.4% upside.

In a report issued on March 15, Morgan Stanley also upgraded the stock to Buy with a $62 price target.

Agilent’s market cap is currently $17.08B and has a P/E ratio of 34.17. The company has a book value ratio of 3.9948.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Rodney Gonsalves, the V.P., Corporate Controller of A sold 8,496 shares for a total of $442,217.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agilent Technologies, Inc. engages in the provision of core bio-analytical and electronic measurement solutions to the life sciences, chemical analysis, communications and electronics, diagnostics and genomics industries. It operates through the following segments: Life Sciences; Chemical Analysis; Diagnostics and Genomics; and Electronic Measurement. The Life Sciences segment provides application-focused solutions that include instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. The Chemical Analysis segment manufactures gas chromatography mass spectrometry systems, inductively coupled plasma mass spectrometry instruments, atomic absorption instruments, inductively coupled plasma optical emission spectrometry instruments, molecular spectroscopy instruments, vacuum pumps and measurement technologies supports and services. The Diagnostics and Genomics segment provides solutions that include reagents, instruments, software and consumables that enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. The Electronic Measurement segment provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment and microscopy products. The company was founded in 1999 and is headquartered in Santa Clara, CA.